Israeli Chiasma To Receive Up To $590M From Swiss Giant Roche AG

Biopharmaceutical company Chiasma Inc., which develops oral drugs that were previously only available by injection, has signed a strategic development agreement with Swiss pharmaceutical giant Roche AG. According to the agreement, Chiasma will receive a down payment of $65 million, and up to $530 million more in milestone payments.